News & Updates

Cancer cases are on the rise in Malaysia with a significant impact on the population’s health. According to the Ministry of Health (MOH), 1-in-10 men and 1-in-9 women are at risk of being diagnosed with cancer during their lifetime.

Adding subcutaneous daratumumab to the three-drug regimen containing bortezomib, lenalidomide, and dexamethasone (VRd) appears to improve outcomes for transplant-eligible patients with newly diagnosed multiple myeloma (MM), with extended disease-free periods and increased depth of response, according to the phase III PERSEUS trial.

First-line combination immuno-oncology therapy (IO) with ipilimumab and nivolumab provides beneficial effects and has an acceptable safety profile in patients with metastatic renal cell carcinoma, as shown in a Japan study presented at ESMO Asia 2023.